UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C . 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 11, 2017
BIOSTAGE, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-35853 | 45-5210462 |
(State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
84 October Hill Road, Suite 11, Holliston, MA | 01746 |
(Address of principal executive offices) | (Zip Code) |
Registrant's telephone number, including area code: (774) 233-7300
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 1.01. | Entry Into a Material Definitive Agreement. |
On December 11, 2017, Biostage, Inc. (the “Company”) entered into a binding Memorandum of Understanding (the “MOU”) with Bin Zhao (including such investor’s designees, the “Investors”), pursuant to which the Company will issue to the Investors in a private placement (the “Private Placement”) 40,000,000 shares of its common stock at a purchase price of $0.10 per share or, to the extent the Investors, following the transaction, would own more than 49.99% of the Company’s common stock, shares of a new class of preferred stock of the Company (the “Preferred Stock”) with a per-share purchase price of $1,000. Pursuant to the terms of the MOU, on December 11, 2017, the Investors paid a $300,000 deposit towards the purchase price for the Private Placement.
Additionally, the Investors will receive warrants (the “Warrants”) to purchase 60,000,000 shares of the Company’s common stock (or, to the extent the Investors would more than 49.99% of the Company’s common stock, shares of Preferred Stock). The Warrants will have an exercise price of $0.10 per share.
The Preferred Stock will be entitled to vote on any matters to which shares of the Company’s common stock are entitled to vote, on an as-if-converted basis. The Preferred Stock will include an ownership limitation that will limit the Investors and their affiliates to owning no more than 49.99% of the Company’s common stock. Additionally, the Company has agreed to grant board representation and nomination rights to Investors and their affiliates, with two director nominees initially and, to the extent that the Investors and their affiliates beneficially own more than 50% of the Company’s common stock (assuming conversion of all shares of Preferred Stock held by such persons), enough director nominees such that the director nominees of the Investors and their affiliates shall constitute a majority of the Company’s board of directors (but no more than is necessary to constitute such a majority).
Pursuant to the MOU, the Company may identify other investors who may participate in the Private Placement on the same financial terms as the Investors, for gross proceeds of up to $2.0 million. In the event such other investors participate in the Private Placement, then the Investors may elect to purchase additional securities in the Private Placement, on the same terms, to the extent necessary to maintain the same post-transaction percentage of voting power that the Investors would have received if no such additional parties participated in the Private Placement.
The Private Placement is conditioned on satisfaction of customary closing conditions and on the Company completing a reverse stock split, as previously approved by its stockholders, such that the Company will have sufficient authorized but unissued shares of common stock to accommodate the issuance of shares of common stock in the Private Placement, along with all shares of common stock issuable upon exercise of the Warrants and conversion of the Preferred Stock. The numbers of securities, purchase price per share of common stock and exercise price of the Warrants will be adjusted to reflect such reverse stock split. The definitive agreements relating to the Private Placement will include customary representations, warranties and covenants. The MOU is binding upon both the Company and Bin Zhao.
The MOU is filed as Exhibit 10.1 to this Current Report on Form 8-K. The foregoing summary of the MOU is subject to, and qualified in its entirety by, the text of the MOU, which is incorporated herein by reference.
Item 3.02. | Unregistered Sale of Equity Securities. |
The information contained above in Item 1.01 related to the shares of common stock, the shares of Preferred Stock and the Warrants is hereby incorporated by reference into this Item 3.02. The shares of common stock, the Warrants (including shares of common stock issuable upon exercise of the Warrants) and the shares of Preferred Stock (including shares of common stock issuable upon conversion of the Preferred Stock) will be sold and issued without registration under the Securities Act of 1933 (the “Securities Act”) in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws.
Item 8.01. | Other Events. |
On December 14, 2017, the Company issued a press release announcing its entry into the MOU with Bin Zhao. The full text of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 8.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
Exhibit
Number |
Title | |
10.1 | Memorandum of Understanding by and between Biostage, Inc. and Bin Zhao, dated December 11, 2017. | |
99.1 | Press Release issued by Biostage, Inc. on December 14, 2017. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BIOSTAGE, INC. | ||
(Registrant) | ||
December 14, 2017 | /s/ Thomas McNaughton | |
(Date) | Thomas McNaughton | |
Chief Financial Officer |
INDEX TO EXHIBITS
Exhibit
Number |
Description of Exhibit | |
10.1 | Memorandum of Understanding by and between Biostage, Inc. and Bin Zhao, dated December 11, 2017. | |
99.1 | Press Release issued by Biostage, Inc. on December 14, 2017. |
Exhibit 10.1
MEMORANDUM OF UNDERSTANDING
This Memorandum of Understanding (“MOU”) is entered into effective as of December 11, 2017 (the “Effective Date”) between Biostage, Inc., a Delaware corporation (the “Company”), Bin Zhao (the “Investor”, provided further that “Investors” as used herein shall individually and collectively mean and include the Investor and any entities that the Investor may designate to purchase the securities at the Closing as provided below), and, solely for the purposes of clause (iv) of Section 3 herein, James McGorry and Thomas McNaughton. The Company and Investors are at times individually referred to herein as a “Party” and, collectively, as the “Parties.”
In consideration of the mutual covenants and agreements contained herein and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree to the terms and provisions of this MOU.
1. Investors jointly and severally agree to purchase, and the Company agrees to sell to the Investors (including any entities that the Investors designate to purchase the securities at the Closing), (i) an aggregate of 40,000,000 shares of the Company’s common stock at a price of $0.10 per share or, to the extent such sale of common stock would cause the Investors to collectively beneficially own more than 50% of the Company’s outstanding common stock following such sale, shares of a new series of convertible preferred stock (the “Preferred Stock”) with a price per share of $1,000.00, and (ii) warrants (the “Warrants”) to purchase an aggregate of 60,000,000 shares of the Company’s common stock with an exercise price of $0.10 per share or, to the extent such exercise would cause the Investors to collectively beneficially own more than 50% of the Company’s outstanding common stock following such exercise, shares of Preferred Stock with an exercise price of $1,000.00 per share (such sale, the “Private Placement”), for an aggregate gross price of $4,000,000. The Preferred Stock shall be convertible into common stock at a conversion rate equivalent to $0.10 per share of common stock, to the extent that such conversion does not cause the Investors to collectively beneficially own more than 50% of the Company’s outstanding common stock following such conversion. Holders of the Preferred Stock shall be entitled to vote on an as-converted basis on all matters on which holders of common stock are entitled to vote. The closing of the sale and issuance of common stock as noted above (the “Closing”) shall occur on or before December 22, 2017, unless otherwise agreed by the Parties. To the extent the Company completes a reverse stock split with respect to its outstanding shares of common stock prior to the Closing, the number of shares of common stock to be issued in the Private Placement, price per share of common stock, conversion rate of the Preferred Stock, number of shares underlying the Warrants and exercise price of the Warrants shall be adjusted accordingly.
2. Subject to fiduciary obligations applicable to the Board of Directors and proper qualifications of the Board Designees in accordance with the definitive agreements, the Company agrees to appoint two persons nominated by the Investors (collectively, to the extent properly qualified, the “Board Designees”) to its Board of Directors; provided, however, that if following the Closing and any additional closings with other parties as contemplated by Section 6 herein, the Investors collectively beneficially own more than 50% of the common stock of the Company (assuming conversion of all shares of Preferred Stock held by such Investors), then the Company agrees to appoint additional Board Designees such that the Board Designees constitute a majority of the members of the Board of Directors (but no more than is necessary to reach such a majority). The Company agrees to cause to be created vacancies for such purpose, such actions to be taken as soon as is practicable after the closing.
3. The obligations of Investors under this MOU are subject to the satisfaction of the following conditions: (i) the Company’s Board of Directors shall approve this MOU and its terms; (ii) the Company shall prepare and provide to Investors a budget reasonably acceptable to Investors for 2018 for the Company’s U.S. operations (the “Budget”); (iii) a material adverse event shall not have occurred prior to the execution of the definitive agreements; (iv) James McGorry and Thomas McNaughton shall waive any contractual rights they have to any compensation that is payable solely as a result of a change of control of the Company; and (v) the Company shall have completed a reverse stock split such that it will have sufficient authorized but unissued shares of common stock to accommodate the issuance of shares of common stock in the Private Placement, along with all shares of common stock issuable upon exercise of the Warrants or conversion of the Preferred Stock. The obligations of the Company under this MOU are subject to the Investors making customary representations and warranties, including without limitation, those required to ensure compliance with private placement regulations as well as that each Investor has sufficient cash in immediately available funds to fund its portion of the private placement.
4. In consideration of the covenants and agreements made by the Company contained herein and for good and valuable consideration, concurrently with the execution of this MOU, the Investor has paid a non-refundable cash deposit of USD $300,000.00 to the Company (the “Deposit”). Following payment of the Deposit, the Investors shall have no further rights to the Deposit, and the Company may use the Deposit for any purpose in its sole discretion. Notwithstanding the foregoing, (i) in the event that the Company breaches this MOU prior to the Closing, and the Investors are not in breach hereof at such time, the Company will promptly return the USD $300,000.00 to the Investor that provided such Deposit, and (ii) in the event the Private Placement contemplated hereby is consummated, at the election of Investor that provided such Deposit, the aggregate purchase price paid by the Investors in connection with the Private Placement shall either be reduced by the full amount of the Deposit, or, in the event the Investors fund at least $4,000,000 at the Closing, the Company will return the USD $300,000.00 to the Investor that provided such Deposit at the Closing.
5. The Company hereby represents and warrants that (i) it has terminated its Shareholder Rights Agreement, dated as of October 31, 2013, by and between the Company and Computershare Trust Company, N.A., as successor to Registrar and Transfer Company, and such agreement is no longer effective, (ii) in the course of the Investor’s due diligence investigation relating to the Company, neither the Company nor its officers have made any material misrepresentation of fact to any Investor or failed to disclose a material fact the Company or such officers know regarding any circumstances that could reasonably result in a material adverse effect on the business of the Company, and (iii) no vote or consent of the Company’s stockholders is required in connection with the consummation of the transactions contemplated hereby, including, but not limited to, the Private Placement.
6. The Investors acknowledge and agree that other parties identified by the Company following the execution of this MOU, but before execution of the definitive agreements, may participate in the Private Placement for aggregate gross proceeds of up to $2.0 million on the same financial terms as the Investors and with the same warrant coverage, and that the closing(s) with respect to such additional parties may occur after the Closing, provided that with respect to any such parties that are not collaborators of the Company with respect to the development of product candidates (such as hospitals, medical institutions, or their affiliates), such parties must close and provide the funding on such participation within three (3) business days of the Closing. In the event any such other parties participate in the Private Placement, the Investors may elect, at such other closing or within three (3) business days of such other closing, to purchase additional shares of common stock, Preferred Stock and Warrants, in each case on the same terms as the other securities purchased by the Investors in the Private Placement, to extent necessary to maintain the same post-transaction percentage of voting power that the Investors would have received if no such additional parties participated in the Private Placement.
It is agreed that this MOU sets forth binding obligations of the Parties. The Parties agree to enter into definitive agreements consistent with the terms hereof and containing customary terms and provisions for similar transactions. However, the Parties acknowledge and agree that this MOU sets forth the fundamental terms of their agreement and the failure to enter into definitive agreements shall not affect the binding nature of the terms, provisions and obligations set forth in this binding MOU.
The Parties acknowledge and agree that this MOU is binding on the signatories hereto and constitutes the entire agreement and understanding of the signatories with respect to the subject matter hereof and is not intended to confer on any other person any rights or remedies. Investor’s obligations hereunder may be performed by her affiliates and designees if approved by the Company in its reasonable discretion. The Company hereby agrees that following the execution by the Investors of the definitive documentation for the Private Placement and the Closing thereunder, the individual obligations of Bin Zhao with respect this MOU shall be deemed satisfied in full and such definitive documentation shall govern the obligations of the Investors thereafter. All questions concerning the construction, validity, enforcement and interpretation of this MOU shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regarding to the principles of conflicts of law thereof. Each Party agrees that all legal proceedings concerning the interpretation and enforcement of this MOU shall be commenced exclusively in the state and federal courts sitting in the Commonwealth of Massachusetts.
[Remainder of page left blank intentionally]
IN WITNESS WHEREOF, the Parties have caused this MOU to be executed by their respective officers thereunto duly authorized as of the date first above indicated.
INVESTOR | BIOSTAGE, INC. | ||
/s/ Bin Zhao | By: | /s/ James McGorry | |
Name: Bin Zhao | Name: James McGorry | ||
Title: Chief Executive Officer | |||
Solely for purposes of Section 3, clause (iv): | |||
/s/ James McGorry | |||
Name: James McGorry, individually | |||
/s/ Thomas McNaughton | |||
Name: Thomas McNaughton, individually |
Exhibit 99.1
Biostage Announces Binding Agreement For $4.0 Million Private Placement
– Investment will provide path forward for Biostage -
- Focus remains on continued development in Pediatric Esophageal Atresia and Adult Esophagus -
– Closing and funding expected to occur later this month –
Holliston, MA, December 14, 2017 – Biostage, Inc. (OTCQB: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and trachea, announced today that on December 11, 2017 it entered into a binding Memorandum of Understanding (the “MOU”) with a private investor for the private placement of 40,000,000 shares of the Company’s common stock, or a convertible preferred equivalent, at a purchase price of $0.10 per common share, and warrants to purchase 60,000,000 shares of the Company’s common stock, or a convertible preferred equivalent, for gross proceeds of $4.0 million. The investor advanced a $300,000 deposit on the private placement proceeds concurrently with the MOU’s execution. The Warrants will have an exercise price of $0.10 per common share which would represent an additional $6.0 million in funding to the company if fully exercised in the future. The price per share and warrants, and the exercise price per warrant, represent a 67% premium to the closing price of the Company’s common stock on the trading day prior to the execution of the MOU. Further, the investor understands the need for additional capital to transition Biostage to a clinical-stage company.
Jim McGorry, CEO of Biostage stated, “Biostage has been in survival mode for the past two months since the failure to fund by a prospective investor that we reported in October. Over the past 60 days we preserved our technology by securing all the data, know-how and mission-critical resources. What has emerged is a smaller company with a reduced cash burn and with all critical functions, partnerships, know-how, and assets in place. Through the due diligence process we were able to demonstrate to the investor a focused plan with strong support from scientific advisors and collaborators. We will work with the investor to re-establish normal operations and fund the promise of the company’s technology. This agreement is a fantastic next step forward. Our focus is on closing the private placement, funding and being back in operation at a more efficient size and structure. Or as I like to say, “back-in-business… better”.
The Company expects the private placement closing and funding to occur later this month. Following the funding, the Company plans to schedule a business update investor teleconference.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor may there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Biostage
Biostage is a biotechnology company developing bioengineered organ implants based on the Company's Cellframe ™ technology which combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants. Cellspan implants are being developed to treat life-threatening conditions of the esophagus, bronchus or trachea with the hope of dramatically improving the treatment paradigm for patients. Based on its preclinical data, Biostage has selected life-threatening conditions of the esophagus as the initial clinical application of its technology.
For more information, please visit www.biostage.com and connect with the Company on Twitter and LinkedIn.
Forward-Looking Statements:
Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements in this press release include, but are not limited to, statements relating to the private placement, including the closing and funding thereof, development expectations and regulatory approval of any of our products, including those utilizing our Cellframe technology, by the U.S. Food and Drug Administration, the European Medicines Agency or otherwise, which closings, offerings, expectations or approvals may not be achieved or obtained on a timely basis or at all; or success with respect to any collaborations, clinical trials and other development and commercialization efforts of our products, including those utilizing our Cellframe technology, which such success may not be achieved or obtained on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, our ability to obtain the funding necessary for ongoing operations, our ability to obtain and maintain regulatory approval for our products and our ability to complete the private placement on a timely basis or at all; plus other factors described under the heading "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016 or described in our other public filings. Our results may also be affected by factors of which we are not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Biostage expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.
Investor Relations Contacts:
Tom McNaughton
Chief Financial Officer
774-233-7321
tmcnaughton@biostage.com